When applied topically, trisodium phosphonoformate (PFA) displayed activity against established cutaneous herpesvirus infections in guinea pigs similar to that exhibited by the closely related phosphonoacetic acid (PAA); however, unlike PAA, PFA was not locally skin irritating. The therapeutic benefits of topical application of PFA were clearly evident when application was delayed for 48 h after virus inoculation, at which time lesions were well developed. The therapeutic effect was dependent on the concentration of PFA and the duration of treatment. PFA exhibited significant activity against established infections when administered intraperitoneally, although it was less effective via this systemic route than when applied topically. Arch. Virol., in press). A comparison of the anti-herpesvirus drugs adenine arabinoside (ara-A), cytosine arabinoside (ara-C), 5'-iodo-2-deoxyuridine (IUdR), ribavirin, and phosphonoacetic acid (PAA) on this model revealed that PAA was the only compound exhibiting good therapeutic activity when applied topically (Alenius and Oberg, in press). Also, PAA has been shown to be more active than ara-A, ara-C, IUdR, and ribavirin on cutaneous infection in hairless mice (3). A disadvantage observed with PAA was dermal toxicity at concentrations of 2% or more (3, 6; Alenius and Oberg, in press).
A comparison of different antiviral drugs should be made preferably on an animal model in which infection closely resembles that in humans. Furthermore, to obtain a truly therapeutic situation, treatment should not begin until symptoms are evident. Cutaneous herpesvirus infection in guinea pigs has been investigated previously by Hubler et al. (5) and used by Schafer et al. (9) as a model for human infections. It has been established that the cumulative score and the time to healing are useful as variables in the deternination of antiviral activity (S. Alenius and B. Oberg, Arch. Virol., in press). A comparison of the anti-herpesvirus drugs adenine arabinoside (ara-A), cytosine arabinoside (ara-C), 5'-iodo-2-deoxyuridine (IUdR), ribavirin, and phosphonoacetic acid (PAA) on this model revealed that PAA was the only compound exhibiting good therapeutic activity when applied topically (Alenius and Oberg, in press). Also, PAA has been shown to be more active than ara-A, ara-C, IUdR, and ribavirin on cutaneous infection in hairless mice (3) . A disadvantage observed with PAA was dermal toxicity at concentrations of 2% or more (3, 6; Alenius and Oberg, in press).
The trisodium salt of phosphonoformic acid (PFA; Fig. 1 ) is a new antiviral compound which inhibits cell-free herpesvirus DNA polymerase, prevents herpesvirus plaque formation in cell cultures (4, 8 wise fashion with three areas for vehicle (Tween-glycerol-water) and three areas for substance. The solutions were applied with a micropipette, spread over the infected sites, and allowed to dry on the skin before the animals were placed in cages. The local application of PAA has no effect on adjacent infected areas (Alenius and Oberg, in press) and this has also been observed for PFA. Intraperitoneal treatment was given as 2 ml of sterile solution at pH 7.2. Scoring 8ystem. The score system has been described earlier (Alenius and Oberg, in press). The following scores were given for the appearance of inoculated skin: 0.5, erythematous and slightly edematous; 1, erythema and one or two small vesicles; 2, erythema and numerou small vesicles; 3, numerous large vesicles and, if in close juxtaposition, coalesced; III, vesicles dried, large crusts; II, crusts fallen off to ca. 50%; I, ca. 10% of the crusts remaining; and 0, uninfected or healed areas, no crusts or vesicles.
Na3+L
Na 3' Trauma from the inoculation or traces from the infection can be present. All scoring was done blind. The cumulative score was calculated by adding all scores, roman and arabic, during the course of infection (Alenius and Oberg, in press).
Chemicals. PFA (trisodium salt; molecular weight, 300.2) and PAA (disodium salt; molecular weight, 248.6) were synthesized at the Research and Development Laboratories at Astra Lakemedel by the methods of Nyl6n (7) . Solutions of PFA and PAA were adjusted to pH 6 with HCI or NaOH for topical application and to pH 7.2 for intraperitoneal treatment. A pH below 4 was avoided for PFA due to its instability at acid pH (13). All other chemicals used were of reagent grade.
Statistical methods. Standard statistical procedures including paired t tests were used (10) . and 100 mM PFA and PAA was made by calculating the cumulative score for the treated areas from day 0 through day 14. The time to healing was also determined and the results are given in Table 1 Fig. 4 . Infected areas were treated with 2% PFA solution for 3 days starting at 4 h and 1, 2, 3, 4, and 5 days after inoculation. Control infections were treated with solvent. Early treatment was most effective in preventing the infection from reaching the highest score. The cumulative scores for treated areas were calculated and compared to those of the untreated areas. PFA had good therapeutic activity even when added 2 days after inoculation, but the effect decreased rapidly when treatment was delayed. There was also a corresponding reduction in time to healing. To obtain a 50% reduction in time to healing, it was necessary to initiate treatment no later than 48 h after inoculation.
Number of treatments. The therapeutic effectiveness of 1, 2, 4, and 6 treatments with 2% PFA is compared in Fig. 5 . The experiment shows that fewer than four treatments are not optimal and that six treatments with 2% PFA gave a similar reduction as eight treatments with 3% PFA (100 mM) (see Fig. 2 ). It is evident that fewer than four treatments had little effect on the time to healing. The cumulative score was slightly reduced even after one treatment with 2% PFA, and a good effect was observed after four treatments. No variation in cumulative score was seen when the solvent was used for one, two, four, or six applications.
Intraperitoneal treatment with PFA. Intraperitoneal administration of PFA had a therapeutic effect on cutaneous HSV-1 infection as shown in Fig. 6 . The slight reduction in score observed in Fig. 6 , when 20 mg/kg was used, was significant (P < 0.05), and so was the reduction in time to healing (P < 0.05). At 100 mg/kg the effect was more pronounced, and a significant reduction in cumulative score (P < 0.001) and time to healing (P < 0.001) were obtained. The reduction in cumulative score was significantly better (P < 0.05) at 100 mg/kg than at 20 mg/kg.
The time from inoculation to when the vesicles started to dry and form crusts occurred between days 5 and 6 after intraperitoneal administration of PFA (Fig. 6 ). This usually occurs 1 day later, between days 6 and 7 in this animal model. (1, 3, 9) . Both PFA and PAA had good therapeutic activity when treatment was started after vesicles had appeared. No significant differences in cumulative score or time to healing on HSV-1 infection could be observed when the compounds were compared on an equimolar basis (Table 1 ; Fig. 2 ). This correlates with the similarity in inhibition of HSV-1 DNA polymerase and inhibition of HSV-1 plaque formation observed for PFA and PAA (8; Helgstrand et al., in press). At concentrations higher than 100 mM a companson between PFA and PAA was difficult due to the dermal toxicity of PAA.
The lowest concentration of PAA used topically to obtain an effect on cutaneous infection in mice has been reported to be 5.5 mM (0.1%), and a good effect has been obtained with 55 mM (1%) PAA; however, the treatment was started before symptoms developed (3) . These results correlate with the present findings that a good effect was obtained with 50 mM PFA or PAA both in cumulative score and in the time to healing. The dose-response curve (Fig. 2) showed that a maximal effect was obtained at 100 mM PFA when treatment was initiated 48 h postinoculation. It is not yet possible to correlate the inhibition of HSV DNA polymerase (4, 8; Helgstrand et al., in press) with the activity on cutaneous infection since the intracellular concentration of PFA is not known.
When contemplating use of an antiviral drug, it is of importance to consider how late during infection therapy may be initiated. PFA had a good effect (Fig. 4) on the cumulative score and the time to healing when applied 2 days after inoculation. If initiated 1 day after inoculation when only erythema can be seen, treatment with PFA prevents most of the vesicle fornation. In the human herpes labialis infection, the time to healing is 8 to 10 days (11) compared with 11 days for the guinea pig cutaneous HSV infection used here (Alenius and Oberg, in press). The time to crust formation is 1.8 days from the first symptoms in human herpes labialis (11) and 6 to 7 days from inoculation in the guinea pig The number of treatments has only been tested starting 48 h postinoculation with two daily applications; it was found that 6 applications were required for full activity (Fig. 5) . It is quite likely that the number of applications necessary will depend on both the time of initiation of treatment and the concentration. The number of applications used for good activity on hairless mice has been reported to be 12 for PAA 1% (3) and 6 for 2% PAA (6) .
The slight decrease in average score at low concentrations of PFA or few treatments was the result of a decrease in some areas and no effect in others ( Table 1 ). As the concentration or the number of treatments increased, all areas responded to the treatment.
To reduce possible toxicity, a topical application of a drug on a cutaneous HSV infection is preferable; however, our data show that a systemic treatment also was possible starting 2 days postinoculation (Fig. 6) . A dose of 100 mg of PFA per kg per day had a significant therapeutic activity when the drug was given intraperitoneally for 6 days. This corresponds to the data published for systemic treatment with PAA of cutaneous HSV infection in mice (3) where a good effect was observed at 200 mg/kg/day starting 1 day postinoculation and continuing for 6 days.
The therapeutic activity of PFA on infected guinea pig skin was also evident with HSV-2, and this indicates that PFA could be active on HSV-2 genital infections. The HSV-2 strains tested have resulted in paralysis (Alenius and Oberg, in press), a complication not observed with HSV-1, even though a therapeutic effect on the cutaneous infection was obtained. This paralysis could probably be avoided by administration of HSV hyperimmunserum (12) . The effect of an earlier treatment with PFA or PAA on paralysis has not been investigated.
The good therapeutic activity of PFA and its apparent lack of dermal toxicity in guinea pigs makes it a potential candidate for use on cutaneous infections in humans. Recent results have shown PFA to be active against genital HSV-2 infections in guinea pigs and herpes keratitis in rabbits (S. Alenius 
